Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib Preserved Lung Function and Displayed Broad Anti-Fibrotic Activity in Models of Pulmonary Fibrosis

Thursday, November 13, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive effects of Seralutinib in preserving lung function and its broad anti-fibrotic activity in models of pulmonary fibrosis. These findings suggest that Seralutinib may offer significant therapeutic benefits for patients suffering from this condition. The results highlight its potential role in managing pulmonary fibrosis effectively.
Price reaction · baseline $2.605 (2025-11-13T14:59:00.000Z) · hit during market hours · clean, no other GOSS news in the window
day 0 close · peak
-3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib demonstrated the ability to preserve lung function.
  • The drug showed broad anti-fibrotic activity in models.
  • Results indicate potential benefits for patients with pulmonary fibrosis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib Preserved Lung Function and Displayed Broad Anti-Fibrotic Activity in Models of Pulmonary Fibrosis
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a drug being studied for its effects on pulmonary fibrosis.

How does Seralutinib affect lung function?

Seralutinib has been shown to preserve lung function in models of pulmonary fibrosis.

What activity did Seralutinib display in studies?

It displayed broad anti-fibrotic activity in models of pulmonary fibrosis.

What condition is Seralutinib targeting?

Seralutinib is targeting pulmonary fibrosis and related conditions.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary fibrosis anti-fibrotic lung function
Last updated: Nov 13, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →